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Abstract
Background: Cervical dilation is indicated prior to performing various gynecological
procedures. However, gynecologists are at times confronted with a stenotic or tight
cervix, resistant to dilation. This can be problematic particularly when cervical ripening
has not been attempted hours before the start of the procedure.
Objective: The objective of this study is to investigate the efficacy of administration of
hyoscine butylbromide for cervical dilation for immediate dilation of the tight or stenotic
cervix.
Materials and Methods: In this clinical trial study, a population of 40 women, aged
20-70 yr with stenotic cervix, evidenced by resistance to pass dilator #2 through their
cervical canal were compared. Cervical patency was assessed 10 min following intra-
cervical canal instillation of hyoscine butylbromide.
Results: Cervical width of 57.5% of patients became wider, as evidenced by passage of
the number 4 Hegar dilator through the cervical canal without resistance. Independent
T-tests did not reveal any statistically significant difference between the two groups
based on their age. Fisher Exact test revealed a statistically significant difference
between the two groups based on the prior route of delivery, with a more statistically
significant response in patients who had vaginal deliveries.
Conclusion: Intra-cervical canal instillation of hyoscine butylbromide is effective in
immediate dilation of the tight or stenotic cervix during intra-uterine procedures.
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1. Introduction
Cervical dilation, a process naturally reserved
for childbirth, is a process that is indicated for
various gynecological procedures, including, but
not limited to, endometrial biopsy, hysteroscopy,
endometrial ablation, intrauterine device insertion,
intrauterine insemination, etc. It is known that an
unfavorable cervix, i.e., a non-primed and non-
dilated cervix, poses a great challenge during
these procedures. Prior to the initiation of gyne-
cological procedures, various methods can be
used to achieve ripening of the cervix. The two
main methods of cervical ripening are chemical
vs mechanical dilators. Mechanical dilators such
as the traditional Hern, Hegar, Pratt, Hanks, and
Denniston dilators are used to sequentially dilate
the cervix (1). However, these dilators have been
shown to be associated with numerous complica-
tions, such as uterine perforation, cervical lacer-
ation, infections, and intraperitoneal hemorrhage
(2). Chemical dilators, such as prostaglandin E1
analogues, have been shown to facilitate cervical
dilation and minimize cervical or uterine injuries
during gynecological procedures such as intra-
uterine device insertion (3). They have been
formed based on the concept of the critical role the
prostaglandins play in cervical ripening by increas-
ing inflammatory mediators in the cervix and
inducing cervical remodeling. Similarly, inhibitory
impulses can lead to stenosis of the cervix, further
posing a challenge during gynecological proce-
dures (4). However, it is important to keep in
mind that cervical priming with chemical agents is
typically carried out 2–4 hr prior to the initiation
of the procedure. Another chemical agent that has
been shown to be effective in cervical dilation
is hyoscine butylbromide. Hyoscine butylbromide,
under the trade name of Buscopan, belongs to
a para-sympatholytic group of drugs, and it is
a semisynthetic derivative of Scopolamine. Due
to its anti-cholinergic properties and high affin-
ity for muscarinic receptors on smooth muscles,
with a selectivity on cervico-uterine plexus, it
can lead to dilation of a tight or stenotic cervix.
Hyoscine butylbromide has a half-life of 4.5–5 hr
(5). Its adverse effects following oral administra-
tion include skin reaction, tachycardia, vascular
disorders (Buscopan injection), dry mouth, urinary
retention, and gastric irritation, which are dose-
dependent. However, these side effects could be
mitigated by vaginal administration of hyoscine
butylbromide, leading to a local response and a
more selective effect on the cervix (6). Originally,
the effect of hyoscine butylbromide was investi-
gated for cervical dilation during the active phase
of labor (7). It was shown that it can reduce the
duration of the first stage of labor by overcoming
cervical spasm, through its effect on blockage of
transmission of neural impulses in the intraneural
parasympathetic ganglia of abdominal organs (8).
Our previous study demonstrated the efficacy of
hyoscine butylbromide in cervical dilation in pre-
menopausal women compared to control group
when administered 8 hours and then 2 hours prior
to the start of intrauterine gynecological proce-
dures (6). However, the application of the men-
tioned pharmacologic agents for cervical ripening
is time-consuming, making them unsuitable for use
for immediate dilation of the cervix.
Our study aims to test the efficacy of intra-
operative or procedural instillation of hyoscine
butylbromide in the cervical canal for immediate
dilation of the cervix during gynecologic proce-
dures.
2. Materials and Methods
2.1. Study patients
The study was conducted at the Department
of Obstetrics and Gynecology at Sirjan Gharazi
Hospital in Kerman, Iran from February 2018 to
March 2018. Patients who were enrolled in this trial
met the following criteria: women not pregnant at
the time of the study, the age range of 20–70 yr,
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in general, good health, and stenotic cervix deter-
mined by obstetrics exam-scheduled for intrauter-
ine procedures due to a gynecological disorder
or for intra-uterine device insertion. Patients who
had any of the following criteria were not enrolled
in the study: prior hypersensitivity to hyoscine
butylbromide, heart disease, thyroid disease, or
hypertension, the temperature of 38ºC or higher,
uterine pain, or any odorous vaginal secretions.
Of note, no patient was on hormonal replacement
therapy at the time of the study. In addition, no
patient in the study had any history of cervical
conization, loop electrical excision procedure, or
cervical incompetency.
2.2. Study design
The study included 40 women based on the
mentioned criteria. Selection of the patients was
based on the history and obstetrics exam that
was carried out by the attending physician on
the patient in lithotomy position immediately prior
to the start of the procedure. Cervical patency
was measured using dilator #2. Those patients in
whom the dilator was not able to pass through
their cervical canal, indicating a stenotic cervix,
were included in this trial. Hyoscine Butyl Bromide
(Vial 20 mg, Osve Company, Iran) under the trade
name of Buscopan via instillation to the cervical
ostium was administered to each patient. Each
patient received contents of the 20 mg vial as
a single dose. Cervical patency was assessed
10 min following the administration of hyoscine
butylbromide, based on the diameter of the largest
Hegar dilator that could be inserted into the cervix
without any resistance.
2.3. Ethical consideration
Prior to the enrollment in the trial, appropriate
written informed consent thoroughly explaining
the purpose of the study, advantages, and disad-
vantages of hyoscine butylbromide administration
were obtained from each patient. The clinical
trial was approved by the Ethics Committee of
Shahid Beheshti University of Medical Science
(IR.SBMU.RETECH.REC.1396.623) and it was regis-
tered within the Iranian registry of clinical trials.
2.4. Statistical analysis
The data were analyzed using SPSS (Statistical
Package for the Social Sciences, version 21.0 SPSS
Inc, Chicago, Illinois, USA); Chi-Square test, Mann-
Whitney U-test, and T-Independent test were used
to compare the results with a statistically significant
result threshold p < 0.05.
3. Results
The demographic characteristics of the study
patients are listed in Table I. Among the 40 patients
who participated in this study, 10 min following the
administration of hyoscine butylbromide, cervical
width of 23 out of 40women (57.5%) becamewider,
as evidenced by passage of number 4 Hegar dila-
tor through the cervical canal without resistance,
10 minutes after intra-cervical canal instillation of
Hyoscine, becamewider. The remaining 17 patients
had no change in their cervical width in the first
10 minutes following the administration of hyoscine
butylbromide.
The average age of patients who had dilation
of the cervix was lower than the group with
no cervical dilation - 37 yr vs. 43 yr. However,
Independent T-test was performed on the two
groups: 23 women who responded to hyoscine
butylbromide administration and the 17 who did not
have any change, based on their age. The results
did not reveal any significant difference between
the two groups based on age (Table II). Fisher Exact
test revealed a significant difference between the
response of women based on their prior route of
delivery. Women who had a natural delivery in the
past responded to the drug in the best way (75%)
in comparison to the women who had only had
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cesarean delivery in their past history (60%), and
the least response corresponded to the group of
patients who were nulliparous (p = 0.013) (Table III).
Mann-Whitney U-test pointed out that the num-
ber of the previous pregnancy, any prior history
of vaginal delivery, or history of C-section did not
affect response to hyoscine butylbromide adminis-
tration. This is despite the fact that previously we
proved that prior route of delivery, not taking to
account the number of deliveries, has a statisti-
cally significant influence on response to hyoscine
butylbromide.
Following the application of the drug, the cervi-
cal width of premenopausal women changed in 19
out of 29womenbut 4 out of 11 menopausal women
showed this shift (p = 0.153) (Table IV).
Furthermore, Fisher Exact test did not reveal any
statistically significant difference in cervical width
between pre-menopausal and post-menopausal
women (Table V).
Figure 1 summarized the study design and the
results of the dilation of cervix based on age,
menopausal status, and history of prior vaginal
delivery.
Table I. Independent T-test results on two groups with/without a change in cervical width after the administration of hyoscine
butylbromide and average age of each group
Hegar dilator # Number Average age Std. deviation Std. error mean T-test
2.0 17 43.706 17.6308 4.2761
4.0 23 36.783 13.3313 2.7798
0.165










Nulliparous 8 1 9
Vaginal delivery 3 9 12
C-section 4 10 14
Both vaginal delivery and C-section 2 3 5
0.013
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Table III. Mann-Whitney U-test on cervical width after the administration of hyoscine butylbromide based on child birth status
Hegar #2 Number of
patients
Hegar #4 Number of
patients
Total Number of patients Mann-Whitney U-test
p-value
Number of Pregnancies
0 8 1 9
1 2 8 10
2 2 7 9
3 4 4 8
4 1 1 2
5 0 2 2
0.073
Number of vaginal deliveries
0 12 11 23
1 2 6 8
2 1 1 2
3 1 2 3
4 1 1 2
5 0 2 2
0.174
Number of C-sections
0 11 10 21
1 2 7 9
2 3 5 8
3 1 1 2
0.331
Table IV. Cervical width after the administration of hyoscine butylbromide based on menopausal state
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Average Age of Participants 40.244





based on age 
 
No statistically significant 
difference based on menopausal 
status 
Statistically significant 
dilation in patients with 
prior history of vaginal 
delivery 
Figure 1. Study Design and Summary of Results based on age, history of vaginal delivery, and menopausal status.
4. Discussion
In this clinical trial, intra-cervical canal instil-
lation of hyoscine butylbromide is effective in
immediate dilation of the tight or stenotic cervix
during intra-uterine procedures, as evidenced by
the dilation of the cervix in 57% of cases. We
observed that the cervical dilation was not different
in pre-menopausal vs post-menopausal women.
Our results also indicated that prior route of
delivery does affect cervical dilation, with more
significant results in patients with prior history of
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vaginal delivery as opposed to Caesarian section;
however, the number of deliveries did not sig-
nificantly affect the response to hyoscine butyl-
bromide administration. Previously, several studies
had introduced various methods for dilation of
the cervix for gynecological procedures. Examples
include the use of mechanical dilation on a non-
primed cervix utilizing the traditional Hern, Hegar,
Pratt, Hanks, and Denniston dilators, the use of
which, as mentioned before, is associated with
higher rates of complications including, but not
limited to, cervical tears, creation of false passages,
and uterine perforation (2). In addition, alternative
methods for cervical dilation were introduced in
several studies using pharmacological methods,
such as prostaglandin E1 analogue - misoprostol
(3) - or hyoscine butylbromide (6), which involves a
lower risk of complications compared to mechan-
ical dilators, but requires administration several
hours prior to the start of gynecological procedures
in order to be effective. The study had indicated
that the administration of hyoscine butylbromide
hours prior to the procedure was effective in
dilating the cervix in pre-menopausal, but not in
post-menopausal women, and the difference was
attributed to the likely difference in the cervical
tissue collagen component and gonadal steroid
deficiency (6). In the same study, our results had
indicated that the administration of vitamin B6 as
placebo did not lead to statistically significant dila-
tion of the cervix when compared to hyoscine butyl-
bromide administration (6). The importance of our
current study is that it has investigated and intro-
duced intra-cervical canal instillation of hyoscine
butylbromide as a novel method for immediate
dilation of a stenotic or tight cervix during the oper-
ation due to its anticholinergic effects on smooth
muscles and its selectivity for the cervico-uterine
plexus. A prior study had demonstrated efficacy of
intramuscular administration of hyoscine butylbro-
mide on reducing the duration of first stage of labor
through hastening cervical effacement and dilation
in primiparous women without labor augmentation,
with no associated increased risk of complications
(9). However, due to the presence of rich cervical
blood supply, the use of hyoscine butylbromide
through direct administration to the cervical ostium
substantially increases its efficacy on dilating the
cervix. Although the use of the drug through this
route has a lot of benefits, the effect of hyoscine
given in this way has rarely been studied.
Based on the results of this study, in more than
half of the cases, there was no need for delaying
the gynecological procedure hours after instillation
of hyoscine butylbromide to observe its efficacy in
dilating the cervix, as the effects were observed
immediately after the administration during the
procedure.
It is notable that because of the limited number
of patients enrolled in this study, a large prospec-
tive study should be conducted in the future
to further confirm the effectiveness of hyoscine
butylbromide.
5. Conclusion
Intra-cervical canal instillation of hyoscine butyl-
bromide is shown to have been effective in more
than half of the study patients in immediate dilation
of the tight and stenotic cervix during intra-uterine
procedures.
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